Ventricular assist system applications in end-stage XXXX .

@entity1 @entity712 @entity548 @entity177 @entity67 @entity204 @entity320 @entity647
BACKGROUND: Mechanical circulatory support has an important role in the surgical therapy for @entity712 . @entity1 deteriorating on transplantation waiting lists or those unsuitable for transplantation have been treated with ventricular assist devices. In this report, we have presented application of ventricular assist systems for @entity1 with end-stage @entity712 . METHODS: Between April 2007 and September 2010, we treated 37 @entity1 with end-stage @entity712 with mechanical circulatory support, including 5 @entity1 younger than 16 years of age. Three @entity1 were females, and the overall mean age was 40    18 years (range, 1.5-67). In 29 @entity1 we implanted paracorporeal pneumatic ventricular assist devices. Axial flow pumps were chosen to support the left ventricle in 8 @entity1 . Biventricular support was applied in 9 @entity1 because of their poor preoperative clinical conditions and advanced evidence of @entity67 . RESULTS: Heart transplantation was performed in 16 @entity1 (43%). One subject, who was managed with a left ventricular assist device implantation and coronary bypass grafting, was weaned from the system because of recovery of ventricular functions. Eleven @entity1 (30%) are still on pump support. Nine @entity1 (24%) died during mechanical circulatory support. The most prevalent cause of mortality was @entity177 (n = 5; 13.5%). @entity548 was the cause of @entity204 in 2 @entity1 . One @entity1 died due to @entity647 , and an other due to @entity320 . CONCLUSION: Use of a ventricular assist device as a bridge-to-transplantation or as destination therapy can be performed with acceptable mortality. It may be the most promising option for @entity1 with end-stage @entity712 . Development of device technology, advanced monitoring of anticoagulation and anti-aggregation therapy, and greater clinical experience may yield better results.
